米拉贝隆治疗膀胱过度活动症的临床应用

doi:10.6040/j.issn.1671-7554.0.2018.074

摘要/Abstract

摘要： 米拉贝隆是一种强效的选择性β₃受体激动剂,是治疗膀胱过度活动症(OAB)有效且耐受性良好的新型药物。临床研究证实,米拉贝隆可明显减少尿失禁次数、排尿次数并增加排尿量,在改善尿急发生和夜尿增多等方面也有很好的疗效,联合抗胆碱能药物后可提高疗效,但不增加药物不良反应发生率,为OAB提供了新的治疗手段,具有良好的应用前景。

关键词: 米拉贝隆, 膀胱过度活动症, β₃受体激动剂, 临床应用

Abstract: As a powerful selective β₃ receptor agonist, mirabegron is an effective and well-tolerated new drug for the treatment of overactive bladder(OAB). Clinical studies have confirmed that mirabegron can significantly reduce the number of urinary incontinence and micturition frequency, increase the average voiding volume, and decrease the urgency 山东大学学报 (医学版)56卷3期 -种铁,等. 米拉贝隆治疗膀胱过度活动症的临床应用 \=-feeling as well as the number of nocturia. Combined with anticholinergic drugs, mirabegron can improve curative effect without increasing the incidence of adverse drug reactions. Mirabegron provides a new treatment method for OAB with a good application prospect.

Key words: Mirabegron, Overactive bladder, β₃-adrenoceptor agonist, Clinical application

中图分类号:

R694

种铁,陈琦. 米拉贝隆治疗膀胱过度活动症的临床应用[J]. 山东大学学报 (医学版), 2018, 56(3): 6-11.

CHONG Tie, CHEN Qi. Clinical application of mirabegron in the treatment of overactive bladder[J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 6-11.

参考文献

[1] 那彦群, 叶章群, 孙颖浩, 等. 2014年版《膀胱过度活动症诊断与治疗指南》[M]. 北京: 人民卫生出版社, 2014: 330-335.
[2] Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China[J]. Neurourol Urodyn, 2011, 30(8): 1448-1455.
[3] Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses[J]. Eur Urol, 2012, 62(6): 1040-1060.
[4] DSouza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended—release and immediate release overactive bladder medications in a regional managed care plan[J]. J Manag Care Pharm, 2008, 14(3): 291-301.
[5] Benner JS, Nichol MB, Rovener ES, et al. Patient-reported reasons for discontinuing overactive bladder of medication[J]. BJU Int, 2010, 105(9): 1276-1282.
[6] Takasu T, Ukai M, Sato S, et al. Effect of(R)-2-(2-aminothiazol-4-yl)-4’-{2-[(-hydroxy-2-phenylethyl)amino] ethyl} acetanilide(YM178), a novel selective beta 3-adrenoceptor agonist, on bladder function[J]. J Pharmacol Exp Ther, 2007, 321(2):642-647.
[7] Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder[J]. Neurourol Urology, 2007, 26(6): 752-756.
[8] Ouslander JG. Management of overactive bladder[J]. N Engl J Med, 2004, 350(8): 786-799.
[9] Michel MC, Cernecka H, Ochodnicky P. Desirable properties of β3-adrenoceptor agonists: implication for the selection of drug development candidates[J]. Eur J Pharamacol, 2011, 657(1-3): 1-3.
[10] Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction[J]. BJU Int, 2012, 110(2b): E132-E142.
[11] Andersson KE, Arner A. Urinary bladder contraction and relaxation drelaxation: physiology and pathophysinology[J]. Physiol Rev, 2001, 84(3): 935-986.
[12] Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium[J]. Naunys Schmiedebergs Arch Pharmacol, 2008, 377(4-6): 473-481.
[13] Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence[J]. Eur Urol, 2011, 59(3): 387-400.
[14] Abrams P, Andersson K, Buccafusco J, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder[J]. Br J Pharmacol, 2006, 148(5): 565-578.
[15] Irwin D, Mungapen L, Milsom L, et al. The economic impact of overactive bladder syndrome in six Western countries[J]. BJU Int, 2009, 103(2): 202-209.
[16] Thiagamoorthy G, Kotes S, Zacchè M, et al. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder[J]. Ther Adv Urol, 2016, 8(1): 38-46.
[17] Limberg B, Andersson K, Aura KF, et al. β-Adrenergic receptor subtype expression in myocyte and nonmyocyte cells in human female bladder[J]. Cell Tissue Res, 2010, 342(2): 295-306.
[18] 李海源, 周逢海, 马玉磊, 等. 膀胱过度活动症治疗新药米拉贝隆[J]. 中国新药杂志, 2014, 23(19): 2215-2218. LI Haiyuan, ZHOU Fenghai, MA Yulei, et al. Mirabegron: a novel drug for overactive bladder symptom[J]. Chinese Journal of New Drugs, 2014, 23(19): 2215-2218.
[19] Balachandran A. The efficacy and tolerability of mirabegron in a non-trial clinical setting[J]. Eur J Obstet Gynecol Reprod Biol, 2016, 200: 63-67. doi: 10.1016/j.ejogrb.2016.02.030.
[20] Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK Clinical Practice[J]. Eur Urol, 2017, 72(3): 389-399.
[21] Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from arandomised, double-blind, dose-ranging, phase 2 study(Symphony)[J]. Eur Urol, 2015, 67(3): 577-588.
[22] Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial[J]. Eur Urol, 2013, 63(2): 283-295.
[23] Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder[J]. J Urol, 2013, 189(4): 1388-1395.
[24] Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder[J]. Urology, 2013, 82(2): 313-320.
[25] Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β₃-adrenoceptor agonist, in patients with overactive bladder in Asia[J]. Neurourol Urodyn, 2015, 34(7): 685-692.
[26] Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder[J]. Eur Urol, 2013, 63(2): 296-305.
[27] Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome[J]. Eur Urol, 2016, 69(2): 311-323.
[28] Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics[J]. Curr Med Res Opin, 2016, 32(4): 621-638.
[29] Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome[J]. Eur Urol, 2005, 47(3): 376-384.
[30] Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience[J]. BJU Int, 2012, 110(11): 1767-1774.
[31] Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada[J]. Can Urol Assoc J, 2015, 9(9-10): 343-350.
[32] Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects[J]. BJU Int, 2005, 95(3):335-340.
[33] Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial[J]. BMC Urol, 2013, 13(18):45-52.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed